AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19797993 — intervention group
Group type: COMPARATOR
Intervention: Breathing air (normoxia)
Number of subjects: 0
Study 16799350 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 20
Study 16799350 — intervention group
Group type: COMPARATOR
Intervention: TIVA (Total Intravenous Anesthesia with Propofol)
Number of subjects: 20
Study 12559648 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 12559648 — intervention group
Group type: EXPERIMENTAL
Intervention: Data monitoring board
Number of subjects: 0
Study 10887047 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal (7.5 g)
Number of subjects: 6
Study 10887047 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal (15 g)
Number of subjects: 6
Study 10887047 — intervention group
Group type: COMPARATOR
Intervention: Diethylcarbamazine (150 mg)
Number of subjects: 6
Study 9326758 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 8
Study 8397726 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyric acid (GHB) 25 mg/kg orally
Number of subjects: 27
Study 8397726 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-hydroxybutyric acid (GHB) in an open study every 2 to 4 hours for the first 2 days and 4 to 6 hours for the following 6 days
Number of subjects: 27
Study 8397726 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB treatment suspended after 8 days
Number of subjects: 27
Study 4091067 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 ppm target CO, $5 per day incentive (n = 11)
Number of subjects: 28
Study 4091067 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 ppm target CO, $4 per day incentive (n = 8)
Number of subjects: 28
Study 4091067 — intervention group
Group type: COMPARATOR
Intervention: 8 ppm target CO, no incentive (n = 9)
Number of subjects: 28
Study 31197218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU/month
Number of subjects: 48
Study 31197218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 75,000 IU/month
Number of subjects: 48
Study 31197218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU/month
Number of subjects: 48
Study 29537446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrosomonas eutropha (D23)
Number of subjects: 0
Study 27120004 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine consumption (via coffee consumption)
Number of subjects: 0
Study 27120004 — intervention group
Group type: COMPARATOR
Intervention: Nicotine deprivation (2 hrs)
Number of subjects: 0
Study 24902628 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions (timed sexual intercourse and assisted reproductive technology)
Number of subjects: 340
Study 24902628 — intervention group
Group type: COMPARATOR
Intervention: Infertile couples (undergoing therapeutic interventions)
Number of subjects: 340
Study 24902628 — intervention group
Group type: COMPARATOR
Intervention: Couples achieving spontaneous pregnancy
Number of subjects: 340
Study 23829056 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 2.5% cream (two applications with one week interval)
Number of subjects: 440
Study 23829056 — intervention group
Group type: COMPARATOR
Intervention: Tenutex emulsion (single whole-body application)
Number of subjects: 440
Study 21377341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 34
Study 21377341 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 34
Study 18192895 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (10 mg)
Number of subjects: 20
Study 18192895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17283867 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric dosing of nitrates
Number of subjects: 26
Study 17283867 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing of nitrates
Number of subjects: 26
Study 17283867 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 26
Study 12803939 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing the number of sex partners
Number of subjects: 0
Study 12803939 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing condom use
Number of subjects: 0
Study 11005946 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant parameter practice
Number of subjects: 72
Study 11005946 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable parameter practice
Number of subjects: 72
Study 11005946 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP learning
Number of subjects: 72
Study 11005946 — intervention group
Group type: EXPERIMENTAL
Intervention: Force and time parameters manipulation
Number of subjects: 72
Study 8947616 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertext access
Number of subjects: 42
Study 8947616 — intervention group
Group type: COMPARATOR
Intervention: Boolean access
Number of subjects: 42
Study 1684481 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporin A formulations
Number of subjects: 23
Study 6793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprobe
Number of subjects: 0
Study 6793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 0
Study 6793183 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 0
Study 6793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain on movement and during physiotherapy
Number of subjects: 0
Study 31759672 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Number of subjects: 44
Study 31327306 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Motivational Interviewing (IMI)
Number of subjects: 215
Study 31327306 — intervention group
Group type: COMPARATOR
Intervention: Single session of Motivational Interviewing (MI)
Number of subjects: 215
Study 28402756 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented manual therapy plus self‐stretching
Number of subjects: 60
Study 28402756 — intervention group
Group type: COMPARATOR
Intervention: Self‐stretching only
Number of subjects: 60
Study 26311526 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced dose radiotherapy
Number of subjects: 0
Study 26311526 — intervention group
Group type: COMPARATOR
Intervention: Standard dose post-operative radiotherapy
Number of subjects: 0
Study 26311526 — intervention group
Group type: COMPARATOR
Intervention: Post-operative chemoradiotherapy
Number of subjects: 0
Study 26311526 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 0
Study 23818718 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab + MTX
Number of subjects: 619
Study 23818718 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 619
Study 21215714 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate for 24 weeks
Number of subjects: 84
Study 21215714 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 2 weeks of prednisone
Number of subjects: 84
Study 19339957 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CD) pretreatment for two weeks before surgery
Number of subjects: 30
Study 19339957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CD pretreatment)
Number of subjects: 30
Study 17305763 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg once daily for 4 weeks
Number of subjects: 103
Study 17305763 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily for 4 weeks
Number of subjects: 103
Study 17305763 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (both dosages)
Number of subjects: 103
Study 15142158 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (23 patients)
Number of subjects: 45
Study 15142158 — intervention group
Group type: COMPARATOR
Intervention: Unstented group (22 patients)
Number of subjects: 45
Study 11158034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of recombinant human GHRH-(1-44)-amide
Number of subjects: 9
Study 11158034 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol supplementation
Number of subjects: 9
Study 11158034 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined stimulation with GHRH and estradiol
Number of subjects: 9
Study 9143859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 1227
Study 9143859 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil
Number of subjects: 1227
Study 9143859 — intervention group
Group type: COMPARATOR
Intervention: Non-users of antimalarials
Number of subjects: 1227
Study 7515644 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF (400 micrograms) subcutaneously days 8-14 of each cycle of intensified COP-BLAM regimen
Number of subjects: 172
Study 7515644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 7515644 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM-CSF
Number of subjects: 172
Study 2960473 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (150 mg tid for 6 weeks)
Number of subjects: 12
Study 2960473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31389201 — intervention group
Group type: EXPERIMENTAL
Intervention: Trelagliptin 25 mg
Number of subjects: 107
Study 31389201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthonasal delivery of linalool (12%) at 6 L/min
Number of subjects: 0
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthonasal delivery of vanillin (25%) at 6 L/min
Number of subjects: 0
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthonasal delivery of low concentration linalool (1.5%)
Number of subjects: 0
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthonasal delivery of low concentration vanillin (6.25%)
Number of subjects: 0
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal delivery of linalool (12%) at 8 L/min
Number of subjects: 0
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Retronasal delivery of vanillin (25%) at 8 L/min
Number of subjects: 0
Study 29401258 — intervention group
Group type: COMPARATOR
Intervention: Control study with orthonasal adaptation using matched stimulus concentrations
Number of subjects: 0
Study 29401258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-adaptation assessment between orthonasal and retronasal pathways
Number of subjects: 0
Study 27450896 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprafascial radial forearm flaps
Number of subjects: 50
Study 27450896 — intervention group
Group type: COMPARATOR
Intervention: Subfascial radial forearm flaps
Number of subjects: 50
Study 27450896 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study 25914018 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plates (VLP)
Number of subjects: 111
Study 25914018 — intervention group
Group type: COMPARATOR
Intervention: External fixation (EF) with adjuvant pins
Number of subjects: 111
Study 25914018 — intervention group
Group type: EXPERIMENTAL
Intervention: VLP (C2 subset)
Number of subjects: 111
Study 25914018 — intervention group
Group type: COMPARATOR
Intervention: EF (C2 subset)
Number of subjects: 111
Study 22967437 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 200
Study 22967437 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 200
Study 22967437 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 200
Study 20545955 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB)
Number of subjects: 43
Study 20545955 — intervention group
Group type: COMPARATOR
Intervention: Psoralen plus ultraviolet A (PUVA)
Number of subjects: 43
Study 18256431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) for lymphatic filariasis, administered annually for four years.
Number of subjects: 0
Study 16109592 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) for 14 weeks
Number of subjects: 40
Study 16109592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16109592 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 40
Study 12520627 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose probenecid (RDP) 2 g at 1 hour before cidofovir
Number of subjects: 24
Study 12520627 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose probenecid (SDP) 2 g at 3 hours before cidofovir, then 1 g at 2 and 8 hours after cidofovir
Number of subjects: 24
Study 12520627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir 5 mg/kg as a 1-hour infusion after saline prehydration
Number of subjects: 24
Study 10799813 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol tablet with sodium bicarbonate (630 mg)
Number of subjects: 0
Study 10799813 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol tablet with sodium bicarbonate (400 mg)
Number of subjects: 0
Study 10799813 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol tablet with calcium carbonate (375 mg)
Number of subjects: 0
Study 10799813 — intervention group
Group type: COMPARATOR
Intervention: Conventional paracetamol tablet (500 mg)
Number of subjects: 0
Study 10799813 — intervention group
Group type: COMPARATOR
Intervention: Soluble paracetamol tablet
Number of subjects: 0
Study 8780277 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 25 micrograms fentanyl (FN)
Number of subjects: 40
Study 8780277 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia with 12.5 mg bupivacaine plus saline (SS)
Number of subjects: 40
Study 1610577 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg IV
Number of subjects: 139
Study 1610577 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 2 ml IV)
Number of subjects: 139
Study 6386936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fenoterol (0.2 mg in each nostril, total 0.8 mg)
Number of subjects: 10
Study 6386936 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fenoterol (0.4 mg inhalation)
Number of subjects: 10
Study 6386936 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fenoterol
Number of subjects: 10
Study 31837238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal outcomes based on baseline platelet count (cutoff, 150 × 10^9/L)
Number of subjects: 202
Study 31837238 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal outcomes in a hypothetical study to prevent decompensation
Number of subjects: 202
Study 30638768 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily)
Number of subjects: 61
Study 30638768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28683357 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (16-week, 3 times per week of heart rate guided-aerobic plus resistance training)
Number of subjects: 49
Study 28683357 — intervention group
Group type: COMPARATOR
Intervention: Control group (recreational activities)
Number of subjects: 49
Study 28683357 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training
Number of subjects: 49
Study 25555415 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 25555415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 25555415 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine and Bupropion
Number of subjects: 0
Study 24021733 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Nutrition Intervention for Community Elders (B-NICE)
Number of subjects: 34
Study 24021733 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 34
Study 21436683 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and ketamine (MK)
Number of subjects: 11
Study 21436683 — intervention group
Group type: COMPARATOR
Intervention: Morphine and saline (MS)
Number of subjects: 11
Study 19766399 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel (Scarfade)
Number of subjects: 45
Study 19766399 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel sheet (Epi-Derm)
Number of subjects: 45
Study 19766399 — intervention group
Group type: COMPARATOR
Intervention: Topical onion extract including heparin and allantoin (Contractubex)
Number of subjects: 45
Study 16463192 — intervention group
Group type: EXPERIMENTAL
Intervention: McPeek score
Number of subjects: 669
Study 12643601 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivin mRNA and protein expression in gastric cancer and surrounding gastric mucosa
Number of subjects: 30
Study 12643601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 expression in gastric cancer
Number of subjects: 30
Study 12643601 — intervention group
Group type: COMPARATOR
Intervention: Caspase-3 expression in normal subjects
Number of subjects: 30
Study 12643601 — intervention group
Group type: EXPERIMENTAL
Intervention: Caspase-3 expression in surrounding gastric mucosa
Number of subjects: 30
Study 11429022 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive ganciclovir treatment for asymptomatic infection
Number of subjects: 90
Study 11429022 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed according to the program
Number of subjects: 90
Study 11429022 — intervention group
Group type: COMPARATOR
Intervention: Non-compliance with the program
Number of subjects: 90
Study 8793575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5 micrograms/kg/min) infused starting 30 min before cardiac catheterization and continued for 6 h thereafter
Number of subjects: 40
Study 1616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation of Dorsalis Pedis (DP) pulse
Number of subjects: 38
Study 1616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation of Posterior Tibial (PT) pulse
Number of subjects: 38
Study 1616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler assessment of PT artery
Number of subjects: 38
Study 1616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler assessment of DP artery
Number of subjects: 38
Study 1616257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure measurements by observers
Number of subjects: 38
Study 1616257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disagreement in DP pulses)
Number of subjects: 38
Study 6203304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate and UVB
Number of subjects: 0
Study 6203304 — intervention group
Group type: COMPARATOR
Intervention: Placebo/UVB
Number of subjects: 0
Study 6203304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate alone
Number of subjects: 0
Study 31028444 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reports by English-speaking radiologists (translated into German)
Number of subjects: 2
Study 31028444 — intervention group
Group type: EXPERIMENTAL
Intervention: German structured reports by German radiologists
Number of subjects: 2
Study 31028444 — intervention group
Group type: COMPARATOR
Intervention: Free-text reports by German radiologists
Number of subjects: 2
Study 29513088 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee polyphenols (CPPs)
Number of subjects: 10
Study 29513088 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 10
Study 26733582 — intervention group
Group type: COMPARATOR
Intervention: Sinus Rhythm at baseline and discharge (SR/SR)
Number of subjects: 1879
Study 26733582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Rhythm at baseline and Atrial Fibrillation at discharge (SR/AF)
Number of subjects: 1879
Study 26733582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation at baseline and discharge (AF/AF)
Number of subjects: 1879
Study 26733582 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation at discharge with lower ventricular response (<90 bpm)
Number of subjects: 1879
Study 24498368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic FLOX (oxaliplatin and 5-fluorouracil)
Number of subjects: 566
Study 24498368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic FLOX + cetuximab
Number of subjects: 566
Study 24498368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy
Number of subjects: 566
Study 24498368 — intervention group
Group type: EXPERIMENTAL
Intervention: Updated plasma YKL‐40 levels after treatment
Number of subjects: 566
Study 21347595 — intervention group
Group type: EXPERIMENTAL
Intervention: Zero calcium score criteria
Number of subjects: 136
Study 21347595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥50% CAD without detectable CAC
Number of subjects: 136
Study 21347595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients diagnosed with ACS
Number of subjects: 136
Study 20739874 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine collagen peptides (MCPs) treatment
Number of subjects: 100
Study 20739874 — intervention group
Group type: COMPARATOR
Intervention: Patient control (carboxymethylcellulose)
Number of subjects: 100
Study 17665470 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy and directed exercise
Number of subjects: 156
Study 17665470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham ultrasound)
Number of subjects: 156
Study 16099892 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP+CrCP model during mental activation tasks
Number of subjects: 13
Study 16099892 — intervention group
Group type: EXPERIMENTAL
Intervention: CVR model during mental activation tasks
Number of subjects: 13
Study 16099892 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP model during mental activation tasks
Number of subjects: 13
Study 16099892 — intervention group
Group type: EXPERIMENTAL
Intervention: CrCP model during mental activation tasks
Number of subjects: 13
Study 12098158 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (men and women)
Number of subjects: 40
Study 12098158 — intervention group
Group type: COMPARATOR
Intervention: Control men
Number of subjects: 40
Study 12098158 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 40
Study 12098158 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with Parkinson's disease
Number of subjects: 40